BENYLIN (diphenhydramine hydrochloride) by Pfizer is clinical pharmacology diphenhydramine hydrochloride is an antihistamine with anticholinergic (drying) and sedative side effects.
Drug data last refreshed 14h ago · AI intelligence enriched 3d ago
BENYLIN is an oral syrup formulation of diphenhydramine hydrochloride, a first-generation antihistamine with anticholinergic and sedative properties. It works by competing with histamine for cell receptor sites on effector cells to relieve allergy and cold symptoms. The drug is widely distributed throughout the body including the CNS, with hepatic metabolism and urinary excretion.
Pre-launch stage indicates early-stage commercial planning with limited team infrastructure; significant growth potential pending market entry.
CLINICAL PHARMACOLOGY Diphenhydramine hydrochloride is an antihistamine with anticholinergic (drying) and sedative side effects. Antihistamines appear to compete with histamine for cell receptor sites on effector cells. Diphenhydramine hydrochloride in the injectable form has a rapid onset of…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions
A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects
Compare Pharmacokinetic (PK) Profiles of Naproxen Sodium, Diphenhydramine Hydrochloride, and Naproxen Sodium and Diphenhydramine Hydrochloride Combination
Bioequivalence Between Two Oral Formulations of Diphenhydramine Hydrochloride
Worked on BENYLIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on BENYLIN offers entry or mid-level career opportunities in launch-phase commercial execution for an established small-molecule OTC/Rx asset. Career trajectory depends on successful market penetration against entrenched generic competition and ability to capture differentiated market segments.